As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...
Novartis lifted the veil on its phase 3 wins in relapsing multiple sclerosis (RMS) announced in early September. | In new ...
In Panku-Lung01, iza-bren, an EGFRxHER3 ADC, significantly reduced the risk of progression or death by 60% compared with ...
With ivonescimab’s first phase 3 win outside lung cancer and a $2 billion investment from AstraZeneca in its U.S. partner ...
This story will be updated Oct. 26 to include detailed Sanovo trial results. | AstraZeneca has offered a detailed look at the ...
TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 ...
The potential new indication could significantly expand Nubeqa's market, with the target population accounting for an estimated 15% of new prostate cancer diagnoses. (iStock/Getty Images Plus) Bayer’s ...
Yesterday, argenx's stock slipped by more than 2%—with its shares still down slightly as of Friday morning—after the Dutch pharma ...
As a snarl of pharma-focused lawsuits from Texas Attorney General Ken Paxton play out, Gilead Sciences has worked out a deal to put its own litigation to bed. | As a snarl of pharma-focused lawsuits ...
The U.S. Treasury Department is closing in on American investments in China's life sciences industry as it issued draft rules ...
With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...
Esteve CDMO, the contract development and manufacturing organization within Spanish specialty pharma Esteve, is overhauling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results